{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:55:53Z","timestamp":1761850553165,"version":"build-2065373602"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1097\/pat.0b013e32834d7bd8","type":"journal-article","created":{"date-parts":[[2011,12,12]],"date-time":"2011-12-12T20:03:54Z","timestamp":1323720234000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Prophylactic human papillomavirus vaccines: past, present and future"],"prefix":"10.1016","volume":"44","author":[{"given":"Lyndal A.","family":"Anderson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0005","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/S0140-6736(07)60947-7","article-title":"Papillomavirus vaccines in perspective","volume":"369","author":"Kahn","year":"2007","journal-title":"Lancet"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0010","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.biologicals.2009.04.005","article-title":"Human papillomavirus vaccines: WHO position paper","volume":"37","year":"2009","journal-title":"Biologicals"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0015","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.ygyno.2010.04.003","article-title":"Measuring serum antibody to human papillomavirus following infection or vaccination","volume":"118","author":"Frazer","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0020","doi-asserted-by":"crossref","first-page":"d1042","DOI":"10.1136\/bmj.d1042","article-title":"Global HPV vaccination","volume":"342","author":"Arie","year":"2011","journal-title":"BMJ"},{"year":"2010","series-title":"Australia\u2019s Health 2010","key":"10.1097\/PAT.0b013e32834d7bd8_bib0025"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0030","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.ygyno.2010.01.027","article-title":"Prevention strategies against human papillomavirus in males","volume":"117","author":"Garland","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0035","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1016\/0090-8258(81)90067-6","article-title":"Papillomavirus infections and human genital cancer","volume":"12","author":"zur Hausen","year":"1981","journal-title":"Gynecol Oncol"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0040","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1002\/anie.200901917","article-title":"The search for infectious causes of human cancers: where and why (Nobel lecture)","volume":"48","author":"zur Hausen","year":"2009","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0045","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nri1260","article-title":"Prevention of cervical cancer through papillomavirus vaccination","volume":"4","author":"Frazer","year":"2004","journal-title":"Nature Rev Immunol"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0050","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0140-6736(07)61416-0","article-title":"Human papillomavirus and cervical cancer","volume":"370","author":"Schiffman","year":"2007","journal-title":"Lancet"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0055","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.yexmp.2009.01.009","article-title":"Recombinant vaccines for the prevention of human papillomavirus infection and cervical cancer","volume":"86","author":"Palmer","year":"2009","journal-title":"Exp Mol Pathol"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0060","doi-asserted-by":"crossref","first-page":"11451","DOI":"10.1128\/JVI.78.21.11451-11460.2004","article-title":"Mechanisms of human papillomavirus-induced oncogenesis","volume":"78","author":"Munger","year":"2004","journal-title":"J Virol"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0065","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/ijc.11691","article-title":"Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins","volume":"109","author":"Duensing","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0070","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/23962","article-title":"Both Rb\/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells","volume":"396","author":"Kiyono","year":"1998","journal-title":"Nature"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0075","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/380079a0","article-title":"Telomerase activation by the E6 gene product of human papillomavirus type 16","volume":"380","author":"Klingelhutz","year":"1996","journal-title":"Nature"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0080","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1101\/gad.8.6.666","article-title":"Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins","volume":"8","author":"White","year":"1994","journal-title":"Genes Dev"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0085","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1158\/0008-5472.CAN-04-0009","article-title":"Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract","volume":"64","author":"Wentzensen","year":"2004","journal-title":"Cancer Res"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0090","doi-asserted-by":"crossref","first-page":"7712","DOI":"10.1128\/JVI.75.16.7712-7716.2001","article-title":"Centrosome abnormalities and genomic instability by episomal expression of human papillomavirus type 16 in raft cultures of human keratinocytes","volume":"75","author":"Duensing","year":"2001","journal-title":"J Virol"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0095","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/sj.onc.1210791","article-title":"Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts","volume":"27","author":"Hafner","year":"2008","journal-title":"Oncogene"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0100","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2217\/fvl.10.73","article-title":"HPV-DNA integration and carcinogenesis: putative roles for inflammation and oxidative stress","volume":"6","author":"Williams","year":"2011","journal-title":"Future Virol"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0105","doi-asserted-by":"crossref","first-page":"S3\/106","DOI":"10.1016\/j.vaccine.2006.05.110","article-title":"Chapter 12: Prophylactic HPV vaccines: underlying mechanisms","volume":"24","author":"Stanley","year":"2006","journal-title":"Vaccine"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0110","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.vaccine.2005.09.002","article-title":"Immune responses to human papillomavirus","volume":"24","author":"Stanley","year":"2006","journal-title":"Vaccine"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0115","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/oxfordjournals.jncimonographs.a003476","article-title":"Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia","volume":"31","author":"Schiffman","year":"2003","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0120","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/jmv.1890460413","article-title":"Prospective study on the development of antibodies against human papillomavirus type 6 among patients with condyloma acuminata or new asymptomatic infection","volume":"46","author":"Wikstrom","year":"1995","journal-title":"J Med Virol"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0125","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/0042-6822(92)91251-O","article-title":"HPV-1 L1 protein expressed in cos cells displays conformational epitopes found on intact virions","volume":"190","author":"Ghim","year":"1992","journal-title":"Virology"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0130","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0042-6822(91)90772-4","article-title":"Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles","volume":"185","author":"Zhou","year":"1991","journal-title":"Virology"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0135","doi-asserted-by":"crossref","first-page":"12180","DOI":"10.1073\/pnas.89.24.12180","article-title":"Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic","volume":"89","author":"Kirnbauer","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0140","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1128\/jvi.67.4.1936-1944.1993","article-title":"Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles","volume":"67","author":"Rose","year":"1993","journal-title":"J Virol"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0145","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1006\/viro.1995.1283","article-title":"Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiae","volume":"209","author":"Hofmann","year":"1995","journal-title":"Virology"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0150","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/0264-410X(95)00103-8","article-title":"Vaccination with yeast- expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation","volume":"13","author":"Jansen","year":"1995","journal-title":"Vaccine"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0155","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1517\/13543776.2011.551114","article-title":"Advances in human papilloma virus vaccines: a patent review","volume":"21","author":"Cho","year":"2011","journal-title":"Exp Opin Ther Patents"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0160","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/jnci\/djj144","article-title":"Who invented the VLP cervical cancer vaccines?","volume":"98","author":"McNeil","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0165","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nbt0710-671","article-title":"Intellectual property, technology transfer and manufacture of low-cost HPV vaccines in India","volume":"28","author":"Padmanabhan","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0170","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1128\/JCM.37.10.3316-3322.1999","article-title":"Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients","volume":"37","author":"Brown","year":"1999","journal-title":"J Clin Microbiol"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0175","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of human papillomavirus 16\/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial","volume":"298","author":"Hildesheim","year":"2007","journal-title":"JAMA"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0180","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0185","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.AOG.0000192397.41191.fb","article-title":"Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. (Erratum in Obstet Gynecol 2006;107:1425.)","volume":"107","author":"Mao","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0190","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1086\/522864","article-title":"Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection","volume":"196","author":"Villa","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0195","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60852-6","article-title":"Effect of prophylactic human papillomavirus L1 virus-like- particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials","volume":"369","author":"Ault","year":"2007","journal-title":"Lancet"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0200","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0205","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.ygyno.2010.01.029","article-title":"Globalimplementationofhumanpapillomavirus (HPV) vaccine: lessons from hepatitis B vaccine","volume":"117","author":"Kane","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0210","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.ygyno.2010.01.023","article-title":"The two faces of human papillomavirus","volume":"117","author":"Frazer","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0215","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.vaccine.2010.10.051","article-title":"Worsening disparities in HPV vaccine utilization among 19-26 year old women","volume":"29","author":"Dempsey","year":"2011","journal-title":"Vaccine"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0220","doi-asserted-by":"crossref","unstructured":"Rana M, Paavonen J, Apter DL, Luostarinen T, Pukkala E, Lehtinen MO. Long-term efficacy of human papillomavirus vaccination against hard endpoints: cancer registry-based follow-up of phase 3 efficacy trials (PATRICIA). European Research Organization on Genital Infection and Neoplasia (Eurogin) Congress, Lisbon, 2011. Abstract presentation.","DOI":"10.1136\/sextrans-2011-050109.109"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0225","unstructured":"Kjaer SK. An evaluation for the long-term effectiveness, immunogenicity and safety of GardasilTM in previously vaccinated women. European Research Organization on Genital Infection and Neoplasia (Eurogin) Congress, Lisbon, 2011. Abstract presentation."},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0230","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/S0140-6736(11)60551-5","article-title":"Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study","volume":"377","author":"Brotherton","year":"2011","journal-title":"Lancet"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0235","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ypmed.2008.11.010","article-title":"Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey - Adult 2007","volume":"48","author":"Jain","year":"2009","journal-title":"Prev Med"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0240","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijgo.2010.09.006","article-title":"Knowledge of and attitudes toward the HPV vaccine among multi-ethnic women from urban\/university and rural areas","volume":"112","author":"Wong","year":"2011","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0245","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10979-009-9201-0","article-title":"Who fears the HPV vaccine, who doesn\u2019t, and why? An experimental study of the mechanisms of cultural cognition","volume":"34","author":"Kahan","year":"2010","journal-title":"Law Hum Behav"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0250","first-page":"38","article-title":"The Vioxx pharmaceutical scandal: Peterson v Merke Sharpe & Dohme (Aust) Pty Ltd (2010) 184 FCR 1","volume":"18","author":"Faunce","year":"2010","journal-title":"J Law Med"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0255","doi-asserted-by":"crossref","first-page":"S3\/227","DOI":"10.1016\/j.vaccine.2006.05.102","article-title":"Chapter 27: Research needs following initial licensure of virus-like particle HPV vaccines","volume":"24","author":"Hildesheim","year":"2006","journal-title":"Vaccine"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0260","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1016\/j.vaccine.2010.04.039","article-title":"Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection","volume":"28","author":"Jagu","year":"2010","journal-title":"Vaccine"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0265","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1017\/S0022215110001179","article-title":"Oncogenic impact of human papilloma virus in head and neck cancer","volume":"124","author":"Heffernan","year":"2010","journal-title":"J Laryngol Otol"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0270","doi-asserted-by":"crossref","first-page":"5828","DOI":"10.1016\/j.vaccine.2010.06.068","article-title":"Conjugation of HPV16 E7 to cholera toxin enhances the HPV-specific T-cell recall responses to pulsed dendritic cells in vitro in women with cervical dysplasia","volume":"28","author":"Nurkkala","year":"2010","journal-title":"Vaccine"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0275","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(09)70227-X","article-title":"Development of therapeutic HPV vaccines","volume":"10","author":"Trimble","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0280","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1479-828X.2006.00580.x","article-title":"Human papillomavirus infection: an old disease, a new vaccine","volume":"46","author":"Giles","year":"2006","journal-title":"Aust NZ J Obstet Gynaecol"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0285","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(07)60828-9","article-title":"Human papillomavirus vaccines to prevent cervical cancer","volume":"369","author":"Markman","year":"2007","journal-title":"Lancet"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0290","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1002\/ijc.25915","article-title":"Eurogin 2010 roadmap on cervical cancer prevention","volume":"128","author":"Franceschi","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0295","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1056\/NEJMcpc030026","article-title":"Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 32-2003. A 37-year-old woman with atypical squamous cells on a Papanicolaou smear","volume":"349","author":"Goodman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1097\/PAT.0b013e32834d7bd8_bib0300","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1042\/CS20050369","article-title":"Molecular biology of human papillomavirus infection and cervical cancer","volume":"110","author":"Doorbar","year":"2006","journal-title":"Clin Sci"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302516325880?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302516325880?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T16:16:36Z","timestamp":1758471396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302516325880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0031302516325880"],"URL":"https:\/\/doi.org\/10.1097\/pat.0b013e32834d7bd8","relation":{},"ISSN":["0031-3025"],"issn-type":[{"type":"print","value":"0031-3025"}],"subject":[],"published":{"date-parts":[[2012,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prophylactic human papillomavirus vaccines: past, present and future","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1097\/PAT.0b013e32834d7bd8","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}